The amylin pathway: from Pramlintide to CagriSema

What amylin actually does

Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. Its physiologic roles include postprandial satiety (acting on hypothalamic and brainstem circuits distinct from GLP-1), slowed gastric emptying, suppression of inappropriate postprandial glucagon, and contributions to bone metabolism. The receptor pharmacology — calcitonin receptor heterodimers with RAMP1/2/3 — is distinct from GLP-1 receptor biology.

The clinical relevance of amylin biology becomes apparent in T1D, where the absence of beta cells produces both insulin deficiency and amylin deficiency. Replacing only insulin (the standard of care) leaves the amylin axis unaddressed, which contributes to postprandial glucose excursions that are difficult to control with insulin alone.

Pramlintide: the first generation

Pramlintide (Symlin), FDA-approved in 2005, is a synthetic amylin analog with three amino-acid substitutions that improve the molecule's solubility and reduce its tendency to form amyloid aggregates (a property of native amylin that contributed to its difficulty as a therapeutic). It is approved as an adjunct to mealtime insulin in T1D and T2D patients, addressing the postprandial-glucose-excursion problem that insulin alone cannot fully control.

Pramlintide also produces modest weight loss as a class effect — the satiety and gastric-emptying biology of amylin reduces caloric intake. The weight effect was the basis for early obesity-indication trials, though the three-times-daily injection requirement limited adoption for that use case.

Cagrilintide: the second generation

Cagrilintide is Novo Nordisk's long-acting amylin analog designed specifically for once-weekly dosing — addressing the principal practical limitation of pramlintide. The Phase 2 obesity monotherapy trial (Lau et al., Lancet 2021) showed clinically meaningful weight loss approaching that of semaglutide at the time, supporting continued development.

The strategic value of cagrilintide is less in standalone obesity therapy (where semaglutide and tirzepatide already produce deeper weight loss) and more in combination — specifically, in the CagriSema combination with semaglutide.

CagriSema: the combination

CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly) is the most-watched combination in modern obesity pharmacology. The mechanistic rationale is that GLP-1 and amylin act on different appetite-regulation circuits — GLP-1 through GLP-1 receptors in hypothalamus and brainstem, amylin through calcitonin-receptor heterodimers in distinct circuits — so combination should produce additive (or close to additive) appetite-suppression effects.

The Phase 2 data supports this. Frias et al. (2023) in The Lancet showed CagriSema produced HbA1c and weight reductions superior to either component alone in T2D patients. The Phase 3 REDEFINE program in obesity is ongoing as of 2026, with expected readouts that will determine whether CagriSema becomes a transformational addition to obesity standard of care.

What CagriSema represents in the broader landscape

The CagriSema strategy is meaningful beyond its own clinical-efficacy question. It represents the field's strategic alternative to ever-deeper receptor-stacking molecules (the dual/triple agonist trajectory). Where receptor-stacking adds biology by combining multiple receptor activations into one molecule, CagriSema-style combinations add biology by combining two molecules acting on different receptor systems.

Both strategies are progressing simultaneously. Triple agonism (retatrutide) is the receptor-stacking endpoint within a single molecule; CagriSema is the combination endpoint of two receptor classes in coordinated dosing. The clinical question over the next 3-5 years is which strategy produces better long-term outcomes — depth of weight loss, durability, tolerability, and cardiometabolic benefits.

The honest editorial read

Amylin pharmacology has been quietly important for decades and is becoming visibly important now. The combination strategy with GLP-1 has stronger mechanistic support than most modern peptide combinations — distinct receptor systems, complementary appetite-circuit biology, and Phase 2 data showing the additive effect actually materializes. CagriSema Phase 3 will be one of the more consequential readouts of the 2026-2027 period.